Vanda Pharmaceuticals Inc.
VNDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $198,772 | $192,640 | $254,382 | $268,682 |
| % Growth | 3.2% | -24.3% | -5.3% | – |
| Cost of Goods Sold | $11,314 | $14,796 | $24,282 | $25,629 |
| Gross Profit | $187,458 | $177,844 | $230,100 | $243,053 |
| % Margin | 94.3% | 92.3% | 90.5% | 90.5% |
| R&D Expenses | $74,431 | $76,823 | $85,770 | $75,363 |
| G&A Expenses | $144,514 | $112,383 | $133,885 | $117,347 |
| SG&A Expenses | $146,414 | $112,883 | $136,485 | $124,047 |
| Sales & Mktg Exp. | $1,900 | $500 | $2,600 | $6,700 |
| Other Operating Expenses | $7,273 | $2,090 | $1,516 | $1,478 |
| Operating Expenses | $228,118 | $191,796 | $223,771 | $200,888 |
| Operating Income | -$40,660 | -$13,952 | $6,329 | $42,165 |
| % Margin | -20.5% | -7.2% | 2.5% | 15.7% |
| Other Income/Exp. Net | $17,739 | $20,291 | $4,971 | $199 |
| Pre-Tax Income | -$22,921 | $6,339 | $11,300 | $42,364 |
| Tax Expense | -$4,021 | $3,830 | $5,025 | $9,212 |
| Net Income | -$18,900 | $2,509 | $6,275 | $33,152 |
| % Margin | -9.5% | 1.3% | 2.5% | 12.3% |
| EPS | -0.32 | 0.044 | 0.11 | 0.6 |
| % Growth | -832.3% | -60.3% | -81.7% | – |
| EPS Diluted | -0.32 | 0.044 | 0.11 | 0.58 |
| Weighted Avg Shares Out | 58,149 | 57,381 | 56,462 | 55,548 |
| Weighted Avg Shares Out Dil | 58,149 | 57,558 | 56,983 | 56,922 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $199 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $8,132 | $3,010 | $2,733 | $2,841 |
| EBITDA | -$32,528 | -$10,942 | $9,062 | $45,006 |
| % Margin | -16.4% | -5.7% | 3.6% | 16.8% |